You are here

P&T News

December 24

Launch expected in second quarter of 2015
Treatment contains stronger liraglutide dose than Victoza
Experts suggest less-stringent DBP target for people with diabetes
Findings may offer way to keep current therapies effective

December 23

Experts find benefit in screening all adults without known hypertension
Treatment indicated for patients who have progressed on Yervoy

December 22

New use seen for bisphosphonates
Researcher hopes to improve on ZMapp vaccine
Treatment achieves significant reduction in HDV levels over 4 weeks
Several new drugs win agency nod

December 19

Researchers find tobacco-specific nitrosamines
Risk reduced by 97% in subjects 50 years of age and older
But MARIANNE trial finds Kadcyla treatment options non-inferior
Drug targets women with defective BRCA genes found by new test

December 18

Rate of functional independence nearly twice as high with clot removal versus usual care alone
Newest fluoroquinolone to win agency’s okay
CD3 T-cell engager joins ranks of world’s most expensive cancer treatments
NIH study examines prescribing patterns

December 17

Defendants responsible for ‘unprecedented national tragedy,’ U.S. Attorney says
Largest hospitals will get stronger as smaller ones get weaker, analysts predict
First pathogen-reduction system for plasma approved in U.S.

December 16

Comedian Joan Rivers’ death spurs increased scrutiny
Study data show test predicts risk better in black women
Authors say ERs will need to provide wider range of health-care services
Smoking remains leading cause of preventable death and disease in U.S.

December 15

Vaccine candidate stimulates production of neutralizing antibodies
Reform reduces incidence of preventable, hospital-acquired health problems
Peptide activates innate repair receptor, turns off inflammation
Combo treatment increases progression-free survival versus vemurafinib alone

December 12

Phase III data reported at neuropsychopharmacology meeting
Capecitabine/ibandronate combo no better than ibandronate alone
Finding could lead to new testing and treatment methods
No significant improvement in progression-free survival

December 11

Researchers see no effect on walking pain of lumbar spinal stenosis
Expert warns of return to ‘dark ages’ of medicine
Bortezomib/fulvestrant shows promise in mid-stage trial



From Sovaldi to Ebola: A Wide-ranging Interview with Dr. David Nash

A leading authority on population health, Dr. David Nash is optimistic about the future of disruptive innovation to improve healthcare in the U.S. The interview was conducted by P&T Editor Sonja Sherritze.